Beneficial effects of romosozumab on bone mineral density and trabecular bone score assessed by dual-energy X-ray absorptiometry in a family with osteogenesis imperfecta-Reference-Cited by-同舟云学术

Beneficial effects of romosozumab on bone mineral density and trabecular bone score assessed by dual-energy X-ray absorptiometry in a family with osteogenesis imperfecta

Published:2024-05-08 Issue:7 Volume:35 Page:1303-1304
ISSN:0937-941X
Container-title:Osteoporosis International
language:en
Short-container-title:Osteoporos Int

Author:

Kusakabe Toru^ORCID,Ishihara Yuki,Kitamura Takuya,Yasoda Akihiro,Nanba Kazutaka,Tsuiki Mika,Satoh-Asahara Noriko,Tagami Tetsuya

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00198-024-07089-2.pdf

Reference8 articles.

1. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947–952

2. Adami S, Gatti D, Colapietro F, Fracassi E, Braga V, Rossini M, Tato L (2003) Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 18:126–130

3. Bradbury LA, Barlow S, Geoghegan F, Hannon RA, Stuckey SL, Wass JA, Russell RG, Brown MA, Duncan EL (2012) Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists. Osteoporos Int 23:285–294

4. Kitamura T, Ishihara Y, Kusakabe T, Tsuiki M, Nanba K, Hiroshima-Hamanaka K, Nomura T, Satoh-Asahara N, Yasoda A, Tagami T (2023) A case of osteogenesis imperfecta caused by a COL1A1 variant, coexisting with pituitary stalk interruption syndrome. Endocr J 70:839–846

5. Ohata Y, Kitaoka T, Ishimi T et al (2023) Association of trabecular bone score and bone mineral apparent density with the severity of bone fragility in children and adolescents with osteogenesis imperfecta: A cross-sectional study. PLoS ONE 18:e0290812